Somewhere in the United States tonight, a family will be asked a hard question at the worst possible moment: whether their loved one would have wanted to be a tissue donor.
Most people know organ donation. Far fewer know that tissue donation is considerably more common, or that a single donor can benefit dozens of recipients. Each year in the U.S., tissue banks recover from tens of thousands of donors and distribute more than two million allografts — grafts of human tissue transplanted from one person to another. One donor may help as many as fifty people.
What happens between that conversation and a graft arriving at a clinic is a long, heavily regulated chain of custody that very few people outside the field ever see. Here is what it looks like.
1. Authorization
Nothing proceeds without documented consent — either the donor's own registered decision or authorization from the legal next of kin. Organ procurement organizations and tissue banks handle these conversations under professional standards that also govern follow-up support for donor families.
It is worth pausing on this. Every graft in every clinic began with a family saying yes on one of the worst days of their life.
2. Donor screening
Screening is where most potential donations are ruled out, and it happens in two independent layers.
The Donor Risk Assessment Interview
A structured interview with those who knew the donor covers medical history, social history, travel, behaviors, and exposures relevant to transmissible disease. It is detailed and it is uncomfortable, and it catches risks that laboratory testing alone would miss — particularly recent exposures that have not yet become detectable in blood.
Serologic and molecular testing
Blood samples are tested by a laboratory certified under CLIA for relevant communicable disease agents, including HIV, hepatitis B and C, and syphilis, with additional testing depending on the tissue type. Under FDA regulation, donor eligibility must be formally determined and documented before tissue is released for distribution.
Either layer can disqualify a donor on its own. Both must be satisfactory.
3. Recovery
Recovery occurs under aseptic technique within a defined time window after death, because tissue quality degrades. Recovery technicians work to written procedures, and the process is documented in detail — what was recovered, when, by whom, under what conditions.
The regulatory framework here is 21 CFR Part 1271, the FDA's rule governing human cells, tissues, and cellular and tissue-based products. It sets requirements for screening, testing, processing, labeling, and tracking. Establishments that recover or process tissue must register with the FDA and follow current good tissue practice.
4. Processing
Processing varies enormously by tissue type. Bone may be cleaned, cut, and demineralized. Tendon may be shaped. Amniotic membrane may be cleaned, flattened, and dehydrated or cryopreserved. Each step is validated, meaning the processor has demonstrated on paper and in testing that the method does what it claims to do consistently.
Much of this work happens in facilities accredited by the American Association of Tissue Banks. AATB accreditation is voluntary and goes beyond the regulatory minimum; the great majority of transplanted human tissue in the U.S. comes from AATB-accredited banks.
5. Testing and release
Finished tissue undergoes testing appropriate to its type — sterility testing, and other parameters depending on the product. Results are recorded on a lot-specific certificate of analysis. Only after donor eligibility, processing records, and testing all check out is the tissue released for distribution.
6. Distribution and traceability
Tissue then moves through a validated cold chain, with storage and shipping conditions specified and monitored. Distributors and clinics are required to maintain tracking records that allow any graft to be traced in both directions: from donor to every recipient, and from any recipient back to the donor.
That bidirectional traceability exists for one reason. If a safety issue is ever identified — a donor infection detected after the fact, a processing deviation — every affected graft and every affected patient can be found quickly.
The documentation that should follow every graft
- Donor eligibility determination
- Infectious disease testing results from a CLIA-certified laboratory
- Processing records and validated methods
- Lot-specific certificate of analysis
- Storage and handling requirements
- Lot number and expiration date recorded at the point of use
Why we think this is worth explaining
Human tissue is not an ordinary supply item. It came from a person, it was given by a family, and the systems that carry it from one to the other exist to honor both the gift and the patient who receives it.
That is also why documentation matters more here than in almost any other category a practice purchases. A supplier who can produce the full record on request is demonstrating something about how they operate. One who cannot is demonstrating something too.